Current Report · Items 5.07, 9.01 · 8-K

Profound Medical Corp.

Submission of Matters to a Vote of Security Holders

Filed May 15, 2026Accepted May 15, 2026, 4:06 PM EDTCIK 1628808Accession 0001104659-26-062509

Company context

Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Profound is commercializing TULSA-PRO ®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.

Current securities

PRNTSX · EQUITY · Current PROFNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 5.07, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.07Item 5.07 - Submission of Matters to Vote

Item 5.07. Submission of Matters to a Vote of Security Holders At the 2026 Annual General and Special Meeting of Shareholders of Profound Medical Corp. (the “Company”) held on May 13, 2026, the holders of common shares of the Company voted on: (1) eight director nominees to be elected to the Board of Directors of the Company (the “Board”) to serve until the close of the Company’s next annual meeting of shareholders or until their respective successors have been appointed; (2) the appointment of PricewaterhouseCoopers LLP as auditors of the Company until the close of the Company’s next annual meeting of shareholders at such remuneration to be fixed by the Board; and (3) an ordinary resolution approving all unallocated restricted share units and deferred share units under the Company’s long-term incentive plan. The items of business are further described in the Company’s management information circular filed as Exhibit 99.1 to this Current Report on Form 8-K. The tables below set forth the number of votes cast for, against or withheld, for each matter voted on by the Company’s shareholders. Election of Directors Each of the eight nominees listed below was elected as director of the Company to hold office until the Company’s next annual meeting of shareholders or until their successor is duly appointed. Nominee For % For Withheld % Withheld ─────────────────────────────────────────────────────────────────────────────── Arun Menawat 12,773,374 90.257 1,378,792 9.743 Brian Ellacott 11,541,684 81.554 2,610,482 18.446 Cynthia Lavoie 11,586,793 81.873 2,565,373 18.127 Murielle Lortie 11,586,693 81.872 2,565,473 18.128 Arthur Rosenthal 11,180,113 78.999 2,972,053 21.001 Frank Baylis 12,945,473 91.473 1,206,693 8.527 Thomas Wellner 12,948,509 91.495 1,203,657 8.505 Vafa Jamali 12,885,003 91.046 1,267,163 8.954 Appointment of Auditors The shareholders approved the appointment of PricewaterhouseCoopers LLP as auditors of the Company until the close of the Company’s next annual meeting of shareholders at such remuneration to be fixed by the Board. Votes For % For Votes Withheld % Withheld ────────────────────────────────────────────────────────────── 25,193,910 99.497 127,301 0.503 Approval of Unallocated Restricted Share Units and Deferred Share Units under the Long-Term Incentive Plan The shareholders approved an ordinary resolution approving all unallocated restricted share units and deferred share units under the Company’s long-term incentive plan. Votes For % For Votes Against % Against ─────────────────────────────────────────────────────────── 9,046,376 63.922 5,105,787 36.078

Filed exhibits (1)

EX-99.1 (by filename) tm2614840d1_ex99-1.htm

EX-99.1 2 tm2614840d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 13, 2026 AND MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 2, 2026 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT an annual and special meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares (“Common Shares”) in the capital of Profound Medical Corp. (the “Corporation”) will be held at 2400 Skymark Avenue, Unit 6, Mississauga, Ontario, L4W 5K5, on Wednesday, May 13, 2026 at 10:00 a.m. (Toronto time) and will be broadcast via webcast and may be accessed either by conference call at 1-800-715-9871 (Toll Free) or 1-646-307-1963 (United States) Conference ID: 3397163 or online at https://edge.media-server.com/mmc/p/i3dq4xc9 is for the following purposes: to receive the audited financial statements of the Corporation for the financial year ended December 31, 2025 and the accompanying report of the auditors thereon; ──────────────────────────────────────────────────────────────────────────────────────────────────────────── to elect the …

Open exhibit ↗

Get the free weekly BCS email.